Diagnostische Schritte und Therapieoptionen bei peripheren T-Zell-Neoplasien

Armitage J, Vose J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124–4130 Rodriguez-Abreu D, Filho VB, Zucca E (2008) Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol 26: 8–20 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Vol 2 Khot AS, Matutes E, Kaczmarek PA, et al (2008) Alemtuzumab administered by subcutaneous route is less effective than intravenous route for first line therapy of T-cell prolymphocytic leukaemia: results of a pilot study (UKCLL05). Blood (ASH Annual Meeting Abstracts) 112: Abstract 4204 Garnache-Ottou F, Feuillard J, Ferrand C, et al (2009) Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 145: 624–636 Herling M, Jones D (2007) CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 127: 687–700 Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101: 5007–5009 Suh C, Kang YK, Roh JL, et al (2008) Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 49: 1783–1789 Bishu S, Quigley JM, Schmitz J, et al (2007) F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 48: 1531–1538 Horwitz SM (2007) Management of peripheral T-cell non-Hodgkin's lymphoma. Curr Opin Oncol 19: 438–443 Gallamini A, Stelitano C, Calvi R, et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103: 2474–2479 Lee Y, Uhm JE, Lee HY, et al (2009) Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". Ann Hematol 88: 111–119 Kim TM, Lee SY, Jeon YK, et al (2008) Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 19: 1477–1484 Mourad N, Mounier N, Briere J, et al (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111: 4463–4470 Lee J, Suh C, Park YH, et al (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24: 612–618 Herling M, Patel KA, Teitell MA, et al (2008) High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111: 328–337 Savage KJ, Harris NL, Vose JM, et al (2008) ALK- anaplastic large-cell lymphoma is clini cally and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111: 5496–5504 Willemze R, Jansen PM, Cerroni L, et al (2008) Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111: 838–845 Piccaluga PP, Agostinelli C, Califano A, et al (2007) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117: 823–834 de Leval L, Rickman DS, Thielen C, et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109: 4952–4963 Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D (2004) A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104: 328–335 Jaffe ES, Harris NL, Stein H, Isaacson PG (2008) Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112: 4384–4399 Pfreundschuh M, Trumper L, Kloess M, et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104: 626–633 Glass B, Kloess M, Bentz M, et al (2006) Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107: 3058–3064 Hopfinger G, Eichhorst B, Westermann A, Fink AM, Cramer P, Reinart N, Fingerle-Rowson G, Herling M, Stilgenbauer S DH, Kandler G, Hallek M (2008) TPLL-1 Protocol of the German CLL Study Group (DCLLSG) – a prospective phase II trial of Fludarabine, Mitoxantrone and Cyclophosphamide (FMC) followed by Alemtuzumab consolidation in T-PLL. Blood (ASH Annual Meeting Abstracts): Abstract 1999 Weidmann E, Hess G, Krause SW, Subklewe M, Kruse J, Soekler M, Weisel K, Kim S-Z, Dreyling MH, Jager E (2006) A phase II immunochemotherapy study with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Blood (ASH Annual Meeting Abstracts) 108: 2721 Gallamini A, Zaja F, Patti C, et al (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110: 2316–2323 Kim JG, Sohn SK, Chae YS, et al (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60: 129–134 Porcu P, Lin TS, et al (2007) A phase I trial of subcutaneous (SQ) dose-escalated alemtuzumab in patients with T-cell lymphoproliferative disorders (T-LPD). Blood (ASH Annual Meeting Abstracts): 3417 Kluin-Nelemans JC, Lugtenburg PJ, et al (2008) Alemtuzumab-CHOP for aggressive T-cell lymphoma. A phase II HOVON 69 trial. Blood (ASH Annual Meeting Abstracts): Abstract 1999 d'Amore F, Jerkeman M, Relander T, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Baadsgaard O, Hagberg H (2007) Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma. Blood (ASH Annual Meeting Abstracts): Abstract 3409 Foss F, Sjak-Shie N, Goy A, Advani R, Jacobsen E, Acosta M (2006) A phase II study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: interim analysis. Blood (ASH Annual Meeting Abstracts): Abstract 2461 O'Connor OA, Horwitz S, Hamlin P, et al (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27: 4357–4364 Ferrajoli A, Lee BN, Schlette EJ, et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111: 5291–5297 Siegel D, Mitsiades CS, Rizvi S, Garcia-Vargas J, Howe J, Reiser D, Anderson KC, Richardson P (2008) A phase I study of Vorinostat in Combination with Lenalidomide and Dexamethasone in patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts): Abstract 3705 Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut JA (2005) Single-agent thalidomide induces response in T-cell lymphoma. Eur J Haematol 74: 169–171 Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti GJ, Devereux S (2006) Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica 91: ECR44 Querfeld C, Kuzel TM, Guitart J, Rosen ST (2005) Preliminary results of a phase II study of CC-5013 (Lenalidomide, Revlimid®) in patients with cutaneous T-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 106: Abstract 3351 Reiman T, Chua N, White D, Stewart DA, van der Jagt R, Johnston J, Prasad A, Schwarz H, Zeldis J, Belch AR (2007) First report of a phase II clinical trial of lenalidomide oral therapy for peripheral T-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 110: Abstract 2579 Piekarz R, Frye R, et al (2008) Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood (ASH Annual Meeting Abstracts) 112: 1567 Duvic M, Vu J (2007) Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 43: 585–599 Olsen EA, Kim YH, Kuzel TM, et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109–3115 Kirschbaum M, Popplewell L, Nademanee AP, Pullarkat V, Delioukina M, Zain JM, Matsuoka D, Pulone B, Frankel P, Espinoza-Delgado I, Forman SJ, Gandara D, Newman E (2008) A phase 2 study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in relapsed or refractory indolent Non-Hodgkin's lymphoma. A California cancer consortium study. Blood (ASH Annual Meeting Abstracts): 1564 Catovsky D (1982) Prolymphocytic leukaemia. Nouv Rev Fr Hematol 24: 343–347 Dohner H, Ho AD, Thaler J, et al (1993) Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst 85: 658–662 Dungarwalla M, Matutes E, Dearden CE (2008) Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol 80: 469–476 Keating MJ, Cazin B, Coutre S, et al (2002) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20: 205–213 Ravandi F, Aribi A, O'Brien S, et al (2009) Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27: 5425–5430 Wiktor-Jerzejczak W, van Biezen A, et al (2008) Hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL): a retrospective EBMT analysis. Bone Marrow Transplant 41 [Suppl 1]: S54 (Abstract O286) Jantunen E, D'Amore F (2004) Stem cell transplantation for peripheral T-cell lymphomas. Leuk Lymphoma 45: 441–446 Rodriguez J, Conde E, Gutierrez A, et al (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79: 32–38 d'Amore F, Lauritzsen G, Jantunen E, Hagberg H, Anderson H, Cavallin-Ståhl E, Holte H, Østerborg A, Merup M, Hansen M, Telhaug R, Kuittinen O, Gadeberg O, Delabie J, Sundström C, Ralfkiær E, Vornanen M, Jensen CB (2006) Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL) – A phase II study of the nordic lymphoma group (NLG). Blood (ASH Annual Meeting Abstracts);108 Reimer P, Rudiger T, Geissinger E, et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27: 106–113 Corradini P, Tarella C, Zallio F, et al (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20: 1533–1538 Le Gouill S, Milpied N, Buzyn A, et al (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26: 2264–2271 Hamadani M, Awan FT, Elder P, et al (2008) Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 14: 480–483